| May 12, 2025 | Drugs · Drug Quality Assurance | 4 cited references- 21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not fully followed.
- 21 CFR 211.160(b). Scientifically sound laboratory controls Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
- 21 CFR 211.84(d)(2). Component written specification Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
- 21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
| Voluntary Action Indicated (VAI) |
| Aug 2, 2023 | Drugs · Drug Quality Assurance | None posted | Official Action Indicated (OAI) |
| Apr 22, 2022 | Drugs · Drug Quality Assurance | 4 cited references- 21 CFR 211.100(a). Approval and review of procedures Written procedures are not drafted, reviewed and approved by the appropriate organizational units.
- 21 CFR 211.160(b). Scientifically sound laboratory controls Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans designed to assure that components and in-process materials conform to appropriate standards of identity, strength, quality and purity.
- 21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not fully followed.
- 21 CFR 211.198(a). Procedures to be written and followed Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
| Official Action Indicated (OAI) |
| Sep 1, 2021 | Drugs · Unapproved and Misbranded DrugsDrugs · Drug Quality Assurance | 3 cited references- 21 CFR 211.186(b)(9). Manufacturing Instructions and Specifications The master production and control records are deficient in that they do not include complete instructions.
- 21 CFR 211.160(b). Scientifically sound laboratory controls Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
- 21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
| Voluntary Action Indicated (VAI) |
| Dec 12, 2019 | Drugs · Drug Quality Assurance | 3 cited references- 21 CFR 211.188(b)(8). Labeling Control Records and Label Copies The batch production and control records are deficient in that they do not include complete labeling control records, specimen and copy of labeling.
- 21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not fully followed.
- 21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
| Voluntary Action Indicated (VAI) |
| Dec 19, 2018 | Drugs · Drug Quality Assurance | None posted | No Action Indicated (NAI) |
| Jan 12, 2018 | Drugs · Drug Quality Assurance | None posted | Voluntary Action Indicated (VAI) |
| Nov 10, 2016 | Drugs · Drug Quality Assurance | None posted | Voluntary Action Indicated (VAI) |
| Jan 8, 2016 | Drugs · Drug Quality Assurance | None posted | Voluntary Action Indicated (VAI) |
| Aug 21, 2015 | Drugs · Drug Quality AssuranceDrugs · Unapproved and Misbranded Drugs | 3 cited references- 21 CFR 211.28(a). Protective Apparel Not Worn Protective apparel is not worn as necessary to protect drug products from contamination.
- 21 CFR 211.67(b). Written procedures not established/followed Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
- 21 CFR 211.58. Buildings not maintained in good state of repair Buildings used in the manufacturing, processing, and packing of a drug product are not maintained in a good state of repair.
| Voluntary Action Indicated (VAI) |
| Jun 21, 2013 | Drugs · Unapproved and Misbranded DrugsDrugs · Drug Quality Assurance | 2 cited references- 21 CFR 211.100(a). Absence of Written Procedures There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
- 21 CFR 211.56(b). Written sanitation procedures lacking There is a lack of written procedures describing in sufficient detail the methods, equipment and materials to be used for sanitation.
| No Action Indicated (NAI) |
| Feb 2, 2012 | Drugs · Unapproved and Misbranded DrugsDrugs · Drug Quality Assurance | 8 cited references- 21 CFR 211.188(b)(5). In-process and laboratory control results Batch production and control records do not include in-process results for each batch of drug product produced.
- 21 CFR 211.100(a). Absence of Written Procedures There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
- 21 CFR 211.192. Investigations of discrepancies, failures There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
- 21 CFR 211.110(a). Written in-process control procedures Written procedures are not established that describe the in-process controls and tests to be conducted on appropriate samples of in-process materials of each batch.
- 21 CFR 211.186(b)(9). Manufacturing Instructions and Specifications The master production and control records are deficient in that they do not include complete sampling, testing, procedures, and specifications.
- 21 CFR 211.165(d). Acceptance/Rejection Levels The statistical quality control criteria fail to include appropriate acceptance levels and rejection levels.
- 21 CFR 211.110(a). Control procedures to monitor and validate performance Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
- 21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not fully followed.
| Official Action Indicated (OAI) |
| May 24, 2010 | Drugs · Drug Quality Assurance | 1 cited reference- 21 CFR 211.137(a). Expiration date lacking Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
| Voluntary Action Indicated (VAI) |
| Jun 17, 2009 | Drugs · Drug Quality Assurance | 3 cited references- 21 CFR 211.160(a). Deviations from laboratory control requirements Deviations from written specifications and test procedures are not recorded and justified.
- 21 CFR 211.166(a). Written program not followed The written stability testing program is not followed.
- 21 CFR 211.22(d). Procedures not in writing, fully followed The responsibilities and procedures applicable to the quality control unit are not fully followed.
| Voluntary Action Indicated (VAI) |